Regeneron esmo io presentations highlight potential of fianlimab and libtayo® (cemiplimab) in multiple solid tumor types

Presentations include initial results for an investigational combination of fianlimab (lag-3 inhibitor) and libtayo (pd-1 inhibitor) in advanced non-small cell lung cancer tarrytown, n.y. , dec. 1, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced new and updated data across its oncology pipeline will be presented at the european society for medical oncology immuno-oncology (esmo io) congress 2022 from december 7 to 9 in geneva, switzerland.
REGN Ratings Summary
REGN Quant Ranking